title: Evaluation of tumoral enhancement by superparamagnetic iron oxide particles: comparative studies with ferumoxtran and anionic iron oxide nanoparticles.
abstract: This study was designed to compare tumor enhancement by superparamagnetic iron oxide particles, using anionic iron oxide nanoparticles (AP) and ferumoxtran. In vitro, relaxometry and media with increasing complexity were used to assess the changes in r2 relaxivity due to cellular internalization. In vivo, 26 mice with subcutaneously implanted tumors were imaged for 24 h after injection of particles to describe kinetics of enhancement using T1 spin echo, T2 spin echo, and T2 fast spin echo sequences. In vitro, the r2 relaxivity decreased over time (0-4 h) when AP were uptaken by cells. The loss of r2 relaxivity was less pronounced with long (Hahn Echo) than short (Carr-Purcell-Meiboom-Gill) echo time sequences. In vivo, our results with ferumoxtran showed an early T2 peak (1 h), suggesting intravascular particles and a second peak in T1 (12 h), suggesting intrainterstitial accumulation of particles. With AP, the late peak (24 h) suggested an intracellular accumulation of particles. In vitro, anionic iron oxide nanoparticles are suitable for cellular labeling due to a high cellular uptake. Conversely, in vivo, ferumoxtran is suitable for passive targeting of tumors due to a favorable biodistribution.
authors.affiliation: Department of Radiology, Hôpital Avicenne, Bobigny, France. pierre-yves.brillet@avc.ap-hop-paris.fr
authors.forename: P-Y
authors.initials: PY
authors.lastname: Brillet
authors.forename: F
authors.initials: F
authors.lastname: Gazeau
authors.forename: A
authors.initials: A
authors.lastname: Luciani
authors.forename: B
authors.initials: B
authors.lastname: Bessoud
authors.forename: C-A
authors.initials: CA
authors.lastname: Cuénod
authors.forename: N
authors.initials: N
authors.lastname: Siauve
authors.forename: J-N
authors.initials: JN
authors.lastname: Pons
authors.forename: J
authors.initials: J
authors.lastname: Poupon
authors.forename: O
authors.initials: O
authors.lastname: Clément
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology*; D000818:Animals; D003287:Contrast Media / Q000493:pharmacokinetics; D003911:Dextrans; D004195:Disease Models, Animal; D004578:Electron Spin Resonance Spectroscopy; D045604:Extracellular Fluid / Q000378:metabolism; D052203:Ferrosoferric Oxide; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D007424:Intracellular Fluid / Q000378:metabolism; D007501:Iron / Q000493:pharmacokinetics; D058185:Magnetite Nanoparticles; D008297:Male; D051379:Mice; D008819:Mice, Nude; D049329:Nanostructures; D009368:Neoplasm Transplantation; D010087:Oxides / Q000493:pharmacokinetics; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D012878:Skin Neoplasms / Q000378:metabolism / Q000473:pathology; D013057:Spectrum Analysis; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured
chemical_list: D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; C097921:ferumoxtran-10; D007501:Iron; D052203:Ferrosoferric Oxide
references.citation: Eur Radiol. 1998;8(7):1198-204
references.pmid: 9724439
references.citation: J Magn Reson Imaging. 1994 May-Jun;4(3):301-7
references.pmid: 8061425
references.citation: Magn Reson Med. 1995 Feb;33(2):200-8
references.pmid: 7707910
references.citation: J Magn Reson Imaging. 1993 Jul-Aug;3(4):641-8
references.pmid: 8347958
references.citation: Biomaterials. 2003 Mar;24(6):1001-11
references.pmid: 12504522
references.citation: AJR Am J Roentgenol. 1994 Jan;162(1):201-7
references.pmid: 8273666
references.citation: Magn Reson Med. 2000 May;43(5):633-9
references.pmid: 10800026
references.citation: Magn Reson Imaging. 1994;12 (3):433-42
references.pmid: 8007773
references.citation: Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15256-61
references.pmid: 10611372
references.citation: Eur Radiol. 2001;11(11):2319-31
references.pmid: 11702180
references.citation: Eur Biophys J. 2002 May;31(2):118-25
references.pmid: 12012115
references.citation: Radiology. 2001 Feb;218(2):562-9
references.pmid: 11161179
references.citation: Radiology. 2003 Aug;228(2):480-7
references.pmid: 12819345
references.citation: J Colloid Interface Sci. 1997 Oct 15;194(2):427-33
references.pmid: 9398425
references.citation: J Magn Reson Imaging. 1999 Sep;10 (3):468-73
references.pmid: 10508310
references.citation: AJR Am J Roentgenol. 1995 May;164(5):1147-52
references.pmid: 7717222
references.citation: J Magn Reson Imaging. 1997 Nov-Dec;7(6):1140-5
references.pmid: 9400860
references.citation: Nat Biotechnol. 2000 Apr;18(4):410-4
references.pmid: 10748521
references.citation: J Magn Reson Imaging. 2000 Dec;12 (6):866-72
references.pmid: 11105024
references.citation: Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3030-5
references.pmid: 11867752
references.citation: Eur Radiol. 2004 Oct;14 (10 ):1851-8
references.pmid: 15249981
references.citation: Nat Biotechnol. 2001 Nov;19(11):1013-7
references.pmid: 11689841
references.citation: Magn Reson Med. 2003 Apr;49(4):646-54
references.pmid: 12652535
references.citation: Radiology. 2000 Feb;214(2):568-74
references.pmid: 10671613
references.citation: Biometrics. 1988 Sep;44(3):837-45
references.pmid: 3203132
references.citation: Magn Reson Med. 1989 Jun;10(3):289-301
references.pmid: 2733587
references.citation: J Magn Reson Imaging. 1997 Jan-Feb;7(1):258-63
references.pmid: 9039625
references.citation: J Control Release. 2001 Jul 6;74(1-3):7-25
references.pmid: 11489479
references.citation: Radiology. 1998 Jun;207 (3):799-808
references.pmid: 9609907
references.citation: Invest Radiol. 1992 Jun;27(6):450-5
references.pmid: 1376725
references.citation: Invest Radiol. 2004 Jan;39(1):56-63
references.pmid: 14701989
references.citation: Cancer Res. 1995 Sep 1;55(17):3752-6
references.pmid: 7641188
references.citation: Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12
references.pmid: 9539785